M. Klevesath

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

T. Baère, V. Lazar, J. Soria, 2013, Investigational New Drugs.

Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors.

R. Kurzrock, F. Janku, D. Hong, 2014 .

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

R. Kurzrock, F. Janku, D. Hong, 2019, Clinical Cancer Research.

Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial.

S. Duffy, L. Bobrow, J. Myles, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Dose-Escalation Study of Oral Selective C-Met Inhibitor Emd 1214063 in Patients with Advanced Solid Tumors

R. Kurzrock, S. Stinchi, D. Hong, 2012 .

Touch imprint cytology of core needle biopsy specimens: a useful method for immediate reporting of symptomatic breast lesions.

R. Bannon, E. Coveney, M. Klevesath, 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Patterns of metastatic spread in early breast cancer.

S. Duffy, A. Purushotham, S. Pinder, 2013, Breast.

Lymph Node Status and Breast Cancer-related Lymphedema

S. Duffy, O. Agbaje, A. Purushotham, 2007, Annals of surgery.

Forward Thinking for Sustainable Business Value: A New Method for Impact Valuation

T. Eberle, Alexandra Jürgens, M. Klevesath, 2020 .

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

C. Stroh, G. Falchook, P. Girard, 2021, CPT: pharmacometrics & systems pharmacology.

The value of immunohistochemistry in sentinel lymph node histopathology in breast cancer

A. Purushotham, S. Pinder, L. Bobrow, 2005, British Journal of Cancer.

A Code of Digital Ethics: laying the foundation for digital ethics in a science and technology company

A. Nemat, M. Klevesath, J. Charton, 2022, AI Soc..